Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma. (October 2016)

• Record Type: Journal Article
• Authors: Shen, Limei; Krauthäuser, Susanne; Fischer, Karl; Hobernik, Dominika; Abassi, Yasmin; Dzionek, Andrzej; Nikolaev, Alexej; Voltz, Nicole; Diken, Mustafa; Krummen, Mathias; Montermann, Evelyn; Tubbe, Ingrid; Lorenz, Steffen; Strand, Dennis; Schild, Hansjörg; Grabbe, Stephan; Bros, Matthias
• Is Part Of: Nanomedicine. Volume 11:Number 20(2016)
• Page Start: 2647
• Page End: 2662
• Publication Date: 2016-10
• Subjects: CpG -- CTL -- DEC205 -- dendritic cell -- IFN-γ -- MDSC -- nanoparticles -- targeting -- TNF-α -- tumor therapy; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2016-0174
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: We wanted to assess the potency of a trifunctional nanoparticle (NP) that targeted and activated CD8 + dendritic cells (DC) and delivered an antigen to induce antitumor responses.Materials & methods: The DC targeting and activating properties of ferrous NPs conjugated with immunostimulatory CpG-oligonucleotides, anti-DEC205 antibody and ovalbumin (OVA) as a model antigen to induce antigen-specific T-cell responses and antitumor responses were analyzed.Results: OVA-loaded NP conjugated with immunostimulatory CpG-oligonucleotides and anti-DEC205 antibody efficiently targeted and activated CD8 + DC in vivo, and induced strong OVA-specific T-cell activation. Vaccination of B16/OVA tumor-burdened mice with this NP formulation resulted in tumor growth arrest.Conclusion: CD8 + DC-targeting trifunctional nanocarriers bear significant potential for antitumor immunotherapy.